Latest Breaking News On - Nacuity pharmaceuticals - Page 9 : comparemela.com

Nanoform Interim Report January – March (Q1) 2021

Nanoform Interim Report January – March (Q1) 2021 Nanoform Company Announcement Nanoform Interim Report January – March (Q1) 2021 Strong momentum continues: three new non-GMP lines commissioned, four new clients signed, and six new customer PoC projects commenced. In addition, positive results from first clinical study announced, two near-term business targets achieved (“First Biologics PoC in 2021” and “at least three new non-GMP lines in 2021”), next generation STARMAP ® launched, EUR 40 million successfully raised and commercial teams in the US and the UK further strengthened. 1-3/2021 key financials - Revenue EUR 278 thousand, growth + 85%, stemming from 14 different customer projects (EUR 150 thousand, 6 customer projects in 1-3/2020). - The gross profit and gross margin improved to EUR 243 thousand and 88%, respectively (EUR 103 thousand, 68%).

Eteläuomen läiSan diegoUnited statesUnited kingdomCelanese vitaldoseChris worralMiguel caladoBiologics poVp business developmentFinnish financial supervisory authorityEuropean biotech companyNacuity pharmaceuticalsFinland branchDanske bankCoast us biotech companyCelanese corporation

An End to This Rare Syndrome Could Be an Opportunity for Investors

Apr 7, 2021 at 10:58AM ProQR Therapeutics (NASDAQ:PRQR) is a biotechnology company based in the Netherlands that s currently developing RNA therapies for rare genetic diseases. ProQR is at the moment investigating two treatments for a rare genetic disease called Usher syndrome, QR-421a and QR-411. Though the latter is still in preclinical studies, recent phase 1/2 trial results from the STELLAR trial for QR-421a are promising. When that data was released March 24, ProQR s stock increased from $5.68 to $9.22. As of 10 a.m. April 4, the stock price is currently at $6.50. Could these favorable results mean good things for investors? Let s look into the company and find out.

European medicines agencyDrug administrationNacuity pharmaceuticalsImage sourceUsher syndrome typeEditas medicineபடம் மூலஅஶர் நோய்க்குறி வகை

North Texas Inno - Deals and dollars: A roundup of DFW tech and startup funding rounds, M&As and investor activity in March

North Texas Inno - Deals and dollars: A roundup of DFW tech and startup funding rounds, M&As and investor activity in March
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesFrance generalNorth carolinaFort worthSouth lakeCity of fort worthNew valleyRoger staubachRidenow powersportsDustin parkerJonathan simmonsMark cubanDavid shockleyJoe aragonaJerry king

Aviceda Therapeutics Announces Formation of Executive Team

Posted on 553 Aviceda Therapeutics, a late-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing the composition of the Executive Team that will guide the company through ongoing development of breakthrough, first-in-class therapeutics and continued growth opportunities as a business entity. Serving in key leadership roles on Aviceda’s Executive Leadership Team will be: Mohamed Genead, MD, CEO & President, David Callanan, MD, Chief Medical Officer, Derek Kunimoto, MD, JD, Chief Operating Officer, Michael Tolentino, MD, Chief Technology Officer, and Christopher Scott, PhD, Chief Scientific Officer.

Wills eye hospitalUnited statesUnited kingdomUniversity of illinoisUniversity of texas southwestern medical centerUniversity of texas southwestern medical schoolUniversity of massachusettsMemorial hospitalUniversity of pennsylvaniaMohameda geneadJudah folkmanCraig melloGensight biologicsLauren colellaBevacizumab avastinMohamed genead